• Captopril and Bradykinin: Designing Better Assays

  2026-09-03

  Captopril is an ACE inhibitor whose effects can be interpreted more rigorously by separating angiotensin, bradykinin, and tissue-level readouts. This article translates guinea pig ileum pharmacology into practical assay logic for hypertension research and carefully bounded oncology studies.

• ML216: BLM Helicase Inhibition Beyond WRN Models

  2026-09-02

  Explore ML216, a BLM helicase inhibitor, as a mechanistic probe for DNA repair vulnerabilities, sister chromatid exchange, and cancer-cell dependency. This guide connects BLM biology with the WRN–p53/PUMA findings in MSI colorectal cancer while emphasizing target deconvolution and assay design.

• ω-Agatoxin IVA Suppresses Seizures in Rats

  2026-09-02

  This Molecular Neurobiology study identifies selective Cav2.1 blockade by ω-agatoxin IVA as a way to suppress pentylenetetrazole-induced epileptogenesis while preserving tested motor functions. Its combined EEG, behavioral, and immunohistochemical design links reduced seizure activity with increased BDNF and decreased cleaved caspase-3 expression, providing a mechanistic basis for further epilepsy research.

• DPPH Assay Workflow for Antioxidant Screening

  2026-09-01

  Use DPPH to rapidly rank purified compounds, plant extracts, and cultivation samples by radical-scavenging capacity before committing to deeper profiling. This practical workflow combines fresh reagent preparation, plate-based controls, orthogonal assays, and LC-MS/MS follow-up to separate genuine antioxidant hits from matrix artifacts.

• GSK461364 Targets NEK7 Phosphorylation in NLRP3

  2026-09-01

  A 2025 Advanced Science study identifies the PLK1 inhibitor GSK461364 as a suppressor of NLRP3 inflammasome activation and links this effect to reduced phosphorylation-dependent association between NEK7 and NLRP3. The work connects kinase signaling with inflammasome assembly and shows protective activity in murine endotoxemia and colitis models, while also defining important questions about phosphosite causality and PLK1-related safety.

• SNAI1–PIK3R2/p-EphA2 Axis in Thymic Tumors

  2026-08-31

  A 2024 study identifies SNAI1 as a transcriptional hub that promotes epithelial–mesenchymal transition and preserves cancer stem cell-like properties in thymic epithelial tumors. Multi-omics, functional, single-cell, and tissue-validation experiments connect SNAI1 to a PIK3R2/phosphorylated EphA2 pathway and reveal associated macrophage-state changes, providing a mechanistic framework for future therapeutic studies.

• LIRP Enables Light-Controlled Gene Therapy

  2026-08-30

  The reference study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that regulates therapeutic protein production at the translation stage. In mouse models, LIRP-enabled AAV systems provided light-dependent control of metabolic and retinal gene therapies, suggesting a potential safety layer for chronic treatments that require reversible, on-demand activity.

• Calpain Inhibitor II, ALLM: Practical Assay Workflows

  2026-08-29

  Calpain Inhibitor II, ALLM combines cell permeability with activity against calpain and cathepsin proteases, making it useful for apoptosis, protein-turnover, and protease inhibition assay design. This guide translates its pharmacology into controlled workflows for leukemia, lymphoma, and FAK-proteolysis studies while highlighting selectivity limits and troubleshooting checkpoints.

• Podophyllotoxin Workflows for Cell-Cycle Research

  2026-08-29

  Build reproducible cancer-cell assays around Podophyllotoxin’s microtubule-directed mitotic arrest while separating parent-compound effects from autophagy findings reported for the distinct diterpene JXE-23. The workflow combines dose optimization, cell-cycle profiling, apoptosis confirmation, and autophagic-flux controls for stronger mechanistic conclusions.

• PDHA1 Succinylation Drives α-KGA Immune Escape

  2026-08-28

  A 2025 Nature Communications study identifies PDHA1 lysine 83 succinylation as a metabolic switch in cholangiocarcinoma. The modification increases α-ketoglutarate accumulation, activates OXGR1–MAPK signaling in macrophages, suppresses MHC-II antigen presentation, and may contribute to chemotherapy resistance.

• Chenodeoxycholic Acid: Designing FXR Assays

  2026-08-28

  Chenodeoxycholic Acid is more than an FXR agonist: it is a strategically useful perturbation for connecting bile acid metabolism, transcriptional control, and renal injury phenotypes. This guide translates the CDCA–FXR–KLF11 evidence into a rigorous assay-design framework with practical controls and interpretation limits.

• Masitinib (AB1010): Practical KIT/PDGFR Guide

  2026-08-27

  Masitinib (AB1010), SKU A2942, is a DMSO-compatible research inhibitor for experiments focused on KIT, PDGFRα, PDGFRβ, selected KIT-mutant cell models, and mast-cell responses. It is suitable for controlled in vitro or preclinical workflows, but not for aqueous or ethanol-based assays, broad-spectrum kinase profiling, or direct clinical treatment decisions.

• SIRT4, Glutamine Metabolism, and Liver Fibrosis

  2026-08-27

  The reference study identifies SIRT4-mediated control of glutamate dehydrogenase as a metabolic brake on hepatic stellate cell activation and liver fibrosis. By combining GDH inhibition with SIRT4 overexpression in cellular and animal experiments, it provides a mechanistic framework for targeting glutamine catabolism rather than focusing only on extracellular matrix deposition.

• EdU Imaging Kits (Cy3) for S-Phase Research

  2026-08-26

  EdU Imaging Kits (Cy3) provide a denaturation-free way to measure DNA synthesis in microscopy and flow cytometry workflows. This practical guide connects assay design, click-chemistry optimization, cancer-cell applications, and troubleshooting to cellular senescence research in cholangiocarcinoma.

• 0.4% Trypan Blue Solution: Practical QC Guide

  2026-08-26

  0.4% Trypan Blue Solution supports rapid cell viability measurement and cell counting by differentiating unstained viable cells from blue-stained dead or membrane-damaged cells. It is intended for controlled scientific research workflows, not diagnostic, therapeutic, or medical use.

453 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page